New York State Common Retirement Fund lowered its position in Enzo Biochem, Inc. (NYSE:ENZ) by 0.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,600 shares of the medical research company’s stock after selling 1 shares during the quarter. New York State Common Retirement Fund owned 0.09% of Enzo Biochem worth $448,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Legal & General Group Plc lifted its position in shares of Enzo Biochem by 10.6% in the 2nd quarter. Legal & General Group Plc now owns 10,663 shares of the medical research company’s stock worth $119,000 after acquiring an additional 1,022 shares during the period. KCG Holdings Inc. bought a new position in shares of Enzo Biochem during the 1st quarter worth approximately $141,000. OMERS ADMINISTRATION Corp bought a new position in shares of Enzo Biochem during the 2nd quarter worth approximately $155,000. American International Group Inc. lifted its position in shares of Enzo Biochem by 7.1% during the 1st quarter. American International Group Inc. now owns 24,432 shares of the medical research company’s stock worth $204,000 after buying an additional 1,610 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in shares of Enzo Biochem during the 1st quarter worth approximately $220,000. Institutional investors own 62.46% of the company’s stock.
Enzo Biochem, Inc. (NYSE ENZ) opened at $9.13 on Wednesday. Enzo Biochem, Inc. has a 52-week low of $6.27 and a 52-week high of $12.04.
Several research firms recently commented on ENZ. BidaskClub upgraded Enzo Biochem from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 19th. Zacks Investment Research downgraded Enzo Biochem from a “buy” rating to a “hold” rating in a research report on Tuesday, August 15th. Finally, TheStreet downgraded Enzo Biochem from a “b” rating to a “c+” rating in a research report on Wednesday, September 27th.
TRADEMARK VIOLATION NOTICE: “New York State Common Retirement Fund Trims Holdings in Enzo Biochem, Inc. (ENZ)” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/11/15/new-york-state-common-retirement-fund-trims-holdings-in-enzo-biochem-inc-enz.html.
In related news, EVP James Michael O’brien sold 22,866 shares of the firm’s stock in a transaction on Friday, October 27th. The stock was sold at an average price of $10.28, for a total transaction of $235,062.48. Following the completion of the sale, the executive vice president now directly owns 34,886 shares of the company’s stock, valued at approximately $358,628.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Elazar Rabbani sold 72,401 shares of the firm’s stock in a transaction on Wednesday, October 25th. The shares were sold at an average price of $10.09, for a total value of $730,526.09. Following the sale, the chief executive officer now directly owns 2,038,474 shares of the company’s stock, valued at $20,568,202.66. The disclosure for this sale can be found here. Insiders have sold a total of 191,398 shares of company stock valued at $1,925,292 in the last 90 days. 9.50% of the stock is owned by corporate insiders.
About Enzo Biochem
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.